Skip to Content

Acarix AB ACARIX

Rating as of

Morningstar’s Analysis

Valuation
Currency in SEK
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Acarix AB operates as a medical technology company which is engaged in developing diagnostic tests for cardiovascular diseases primarily in Europe, China, and the United States. Its main activities are to develop, produce and market a new cardiovascular diagnostic method and similar equipment for the same and related services. The company develops the CADScor acoustic device that is designed to be used by doctors to help assess patients' risk of coronary artery disease.

Contact
World Trade Center Malmo, Skeppsgatan 19
Malmo, SE-211 11, Sweden
T +46 104715802
Sector Healthcare
Industry Medical Devices
Most Recent Earnings Jun 30, 2021
Fiscal Year End Dec 31, 2020
Stock Type
Employees 9